Format

Send to

Choose Destination
Clin Infect Dis. 2020 Jan 2;70(2):319-322. doi: 10.1093/cid/ciz439.

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Author information

1
Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles.
2
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
3
Laboratório de HIV, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil.
4
Division of Infectious Diseases, University of North Carolina, Chapel Hill.
5
Department of Medicine, University of KwaZulu-Natal, Pietermaritzburg, Durban, South Africa.
6
Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC.
7
Bridge HIV, Population Health Division, San Francisco Department of Public Health, California.
8
Perinatal HIV Research Unit, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Soweto, South Africa.
9
Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine.
10
ViiV Healthcare, Research Triangle Park, Durham, North Carolina.
11
Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland.
12
Science Facilitation Department, FHI 360, Washington DC.

Abstract

Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

KEYWORDS:

CAB; HIV uninfected; cabotegravir; weight gain

PMID:
31125395
PMCID:
PMC6938971
[Available on 2020-05-24]
DOI:
10.1093/cid/ciz439

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center